SecurityAUPH / Aurinia Pharmaceuticals Inc (05156V102)
Institutional Owners63
Institutional Shares21,794,892
Institutional Value$ 113,208,000 USD

Institutional Stock Ownership and Shareholders

AUPH / Aurinia Pharmaceuticals Inc Institutional Ownership

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has 63 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 21,794,892 shares. Largest shareholders include NEA Management Company, LLC, FMR LLC / Fidelity, Polar Capital LLP, Franklin Resources Inc, Goldman Sachs Group Inc, Vivo Capital, LLC, BlackRock Inc., Orbimed Advisors Llc, Morgan Stanley, and Alyeska Investment Group, L.P..
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/auph"><img src="https://images.fintel.io/us-auph-so.png" alt="AUPH / Aurinia Pharmaceuticals Inc Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-10 13F-HR FRANKLIN RESOURCES INC 1,664,400 1,664,400 0.00 7,540 8,638 14.56
2018-05-11 13F-HR CITADEL ADVISORS LLC 50,922 264
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Put 115,600 44,000 -61.94 524 228 -56.49
2018-05-15 13F-HR UBS Group AG 118,835 115,435 -2.86 538 599 11.34
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 324,500 215,600 -33.56 1,470 1,119 -23.88
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 1,194,550 1,241,995 3.97 5,411 6,446 19.13
2018-05-08 13F-HR Parallel Advisors, LLC 5,000 2,000 -60.00 23 10 -56.52
2018-05-14 13F-HR MORGAN STANLEY 368,189 607,361 64.96 1,668 3,151 88.91
2018-05-11 13F-HR Cutler Group LP 2,500 600 -76.00 11 3 -72.73
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 24,303 0 -100.00 110 0 -100.00
2018-05-11 13F-HR CITIGROUP INC 4,835 3,366 -30.38 23 18 -21.74
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 227,265 146,851 -35.38 1,030 762 -26.02
2018-05-15 13F-HR Point72 Asset Management, L.P. 537,000 0 -100.00 2,433 0 -100.00
2018-05-11 13F-HR Cutler Group LP Put 2,300 0 -100.00 1 0 -100.00
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ Put 0 10,300 0 53
2018-05-14 13F-HR Hudson Bay Capital Management LP 450,000 300,000 -33.33 2,039 1,557 -23.64
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 13,200 26,600 101.52 60 138 130.00
2018-05-11 13F-HR Cutler Group LP Call 4,600 4,800 4.35 1 0 -100.00
2018-05-15 13F-HR Vivo Capital, LLC 1,213,290 1,213,290 0.00 5,496 6,297 14.57
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. Put 25,500 19,000 -25.49 149 97 -34.90
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 127,289 50,922 -59.99 577 264 -54.25
2018-05-02 13F-HR THOMPSON DAVIS & CO., INC. 250 0 -100.00 1 0 -100.00
2018-05-14 13F-HR ProShare Advisors LLC 28,783 38,861 35.01 130 202 55.38
2018-05-10 13F-HR NEA Management Company, LLC 4,808,483 4,808,483 0.00 21,782 24,956 14.57
2018-05-15 13F-HR A.R.T. Advisors, LLC 66,365 0 -100.00 300 0 -100.00
2018-05-11 13F-HR STIFEL FINANCIAL CORP 10,946 21,718 98.41 49 113 130.61
2018-05-02 13F-HR Daiwa Securities Group Inc. 464 2
2018-05-14 13F-HR Bayesian Capital Management, LP 16,300 85
2018-04-18 13F-HR Creative Planning 150,200 158,200 5.33 683 821 20.20
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 6,730 6,730 0.00 31 35 12.90
2018-05-15 13F-HR ORBIMED ADVISORS LLC 1,797,400 626,275 -65.16 8,142 3,250 -60.08
2018-05-15 13F-HR CREDIT SUISSE AG/ 19,279 28,300 46.79 87 147 68.97
2018-05-14 13F-HR Renaissance Technologies LLC 53,001 0 -100.00 242 0 -100.00
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 0 3,000 0 16
2018-05-15 13F-HR We Are One Seven, Llc 11,000 11,000 0.00 50 57 14.00
2018-05-09 13F-HR Candriam Luxembourg S.C.A. 118,000 118,000 0.00 535 612 14.39
2018-05-15 13F-HR Polar Capital LLP 2,300,000 2,500,000 8.70 10,419 12,975 24.53
2018-05-15 13F-HR TWO SIGMA ADVISERS, LP 48,400 37,900 -21.69 219 197 -10.05
2018-05-14 13F-HR Shell Asset Management Co 4,100 5,200 26.83 19 27 42.11
2018-05-04 13F-HR Swiss National Bank 92,400 92,400 0.00 421 486 15.44
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 171,100 245,800 43.66 775 1,276 64.65
2018-04-18 13F-HR Integral Derivatives, LLC Call 10,000 0 -100.00 45 0 -100.00
2018-05-15 13F-HR Invesco Ltd. 10,578 0 -100.00 48 0 -100.00
2018-05-14 13F-HR INFRASTRUCTURE CAPITAL ADVISORS, LLC 19,303 22,003 13.99 87 114 31.03
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 17,107 16,168 -5.49 77 84 9.09
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 19,595 24,217 23.59 89 126 41.57
2018-05-14 13F-HR BROWN BROTHERS HARRIMAN & CO 6,500 6,500 0.00 29 34 17.24
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 46,000 41,500 -9.78 208 215 3.37
2018-05-14 13F-HR HOWE & RUSLING INC 454 387 -14.76 2 2 0.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 9,478 23,155 144.30 42 119 183.33
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 237,353 259,854 9.48 1,075 1,349 25.49
2018-05-15 13F-HR Alyeska Investment Group, L.P. 581,517 576,324 -0.89 2,634 2,991 13.55
2018-05-15 13F-HR BALYASNY ASSET MANAGEMENT LLC 500,000 0 -100.00 2,265 0 -100.00
2018-04-23 13F-HR Financial Architects, Inc 2,000 2,000 0.00 9 10 11.11
2018-05-14 13F-HR Patriot Financial Group Insurance Agency, LLC 11,100 12,200 9.91 57 62 8.77
2018-05-15 13F-HR FIFTH THIRD BANCORP 2,000 2,000 0.00 9 10 11.11
2018-05-14 13F-HR FMR LLC / Fidelity 4,804,481 4,593,481 -4.39 21,764 23,840 9.54
2018-04-26 13F-HR SIMPLEX TRADING, LLC 3,073 16,606 440.38 13 86 561.54
2018-05-09 13F-HR BlackRock Inc. 719,713 1,045,121 45.21 3,261 5,424 66.33
2018-05-15 13F-HR Abingworth LLP 252,129 252,129 0.00 1,142 1,309 14.62
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. 26,500 28,750 8.49 120 149 24.17
2018-05-08 13F-HR STATE TREASURER STATE OF MICHIGAN 22,500 22,500 0.00 102 117 14.71
2018-06-14 13F-HR/A Dynamic Technology Lab Private Ltd 21,093 0 -100.00 96 0 -100.00
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 4,359 3,273 -24.91 25 18 -28.00
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 120,500 43,700 -63.73 546 227 -58.42
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 9,100 1,208 -86.73 42 6 -85.71
2018-04-17 13F-HR Calton & Associates, Inc. 2,000 0 -100.00 11 0 -100.00
2018-05-18 13F-HR TRUST CO OF VERMONT 1,000 1,000 0.00 5 5 0.00
2018-05-10 13F-HR Spark Investment Management LLC 33,700 0 -100.00 153 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 140,360 95,028 -32.30 636 493 -22.48
2018-05-08 13F-HR Cutler Capital Management, LLC 50,000 55,000 10.00 226 285 26.11
2018-05-17 13F-HR Legal & General Group Plc 2,329 12
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 24,941 24,941 0.00 112 129 15.18
2018-05-15 13F-HR Cubist Systematic Strategies, LLC 3,472 0 -100.00 16 0 -100.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 700 700 0.00 3 4 33.33
2018-04-20 13F-HR Steward Partners Investment Advisory, Llc 500 2
2018-05-18 13F-HR LEVIN CAPITAL STRATEGIES, L.P. 10,000 10,000 0.00 45 52 15.56
2018-05-14 13F-HR K2 PRINCIPAL FUND, L.P. Put 12,000 0 -100.00 54 0 -100.00
2018-05-10 13F-HR AWM Investment Company, Inc. 354,520 0 -100.00 1,606 0 -100.00
2018-05-14 13F-HR DRW Securities, LLC 31,300 162
2017-07-13 13F-HR Princeton Alpha Management LP 12,900 0 -100.00 95 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 14,771 14,771 0.00 67 77 14.93
2018-05-15 13F-HR Bank of New York Mellon Corp 11,657 0 -100.00 52 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 0 1,020 0 5
2018-05-15 13F-HR Kazazian Asset Management, LLC 156,126 156,126 0.00 707 810 14.57
2017-05-15 13F-HR R&F Capital Advisors LP 42,576 313
2018-05-15 13F-HR D. E. Shaw & Co., Inc. 232,633 1,207
2018-05-01 13F-HR IRONWOOD INVESTMENT MANAGEMENT LLC 185,865 185,289 -0.31 842 962 14.25
2018-05-11 13F-HR CITADEL ADVISORS LLC Put 44,000 228
2018-05-09 13F-HR Noven Financial Group, Inc. 14,650 0 -100.00 66 0 -100.00
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 92,460 131,030 41.72 419 680 62.29
2018-05-14 13F-HR Oz Management LP 127,200 0 -100.00 576 0 -100.00
2018-05-15 13F-HR Man Group plc 32,800 170
2018-05-11 13F-HR CITADEL ADVISORS LLC Call 26,600 138
AUPH: Aurinia Pharmaceuticals Stock Analysis and Research Report

2017-09-28 - Asif

Aurinia is a clinical stage biopharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8 where clinical, regulatory and business development functions of the Company are conducted. Aurinia has its registered office located at #201, 17904-105 Avenue, Edmonton, Alberta T5S 2H5 where the finance function is performed. The office of the CEO is located in Bellevue, Washington. Aurinia is organized under the Business Corporations Act (Alberta). Aurinia’s By-Law No. 2 was amended at a shareholder’s meeting held on August 15, 2013 to include provisions requiring advance notice for any nominations of directors by shareholders. Aurinia’s Common Shares are currently listed and traded on the NASDAQ under the symbol “AUPH” and on the TSX under the symbol “AUP”. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular LN. Aurinia has the following wholly-owned subsidiaries: ...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

BioSpace Movers and Shakers for Week of June 4th

2018-06-12 biospace
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors. The companies filled the roles with the talent they believe will drive the next stage of growth. (286-1)

Aurinia Pharmaceuticals' (AUPH) CEO Richard Glickman on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Greetings and welcome to the Aurinia Pharmaceuticals Q1 2017 Financial Results. At this time, all participants are in a listen only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (247-1)

Aurinia: Investment Case Gets Stronger

2018-04-04 seekingalpha
Aurinia Pharmaceuticals (NASDAQ:AUPH) recently released its Q4, 2017 results, as well as, provided an update on its pipeline. The company is continuing to progress well with its Phase III AURORA study, which is evaluating lead candidate Voclosporin in lupus nephritis (LN). The company has also expanded its focus area with Voclosporin also being investigated in focal segmental glomerulosclerosis (FSGS) and Voclosporin Opthalmic Solution (VOS) being evaluated in dry eye syndrome (DES). (247-3)

Aurnia Pharmaceuticals: Creating Value While Executing Its Business Strategy

2018-03-20 seekingalpha
Aurinia Pharmaceuticals provided a Q4 2017 and full year 2017 earnings call and company update on March 15, 2017. (249-1)

CUSIP: 05156V102